Home Tools
Log in
Cart

Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides xnum monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No. Product name CAS No. Purity Chemical Structure
T76810 Ganitumab 905703-97-1 98%
Ganitumab
Ganitumab (AMG 479) is a highly potent monoclonal antibody to type 1 insulin-like growth factor receptor (IGF1R). Ganitumab is recognized to bind to IGF1R at low...
T76815 Lexatumumab 845816-02-6 98%
Lexatumumab
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant meso...
T76828 Sonepcizumab 1031360-18-5 98%
Sonepcizumab
Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P. Sonepcizumab has anti-cancer activity and can be used to study metastatic renal cell...
T76831 Tesidolumab 1531594-08-7 98%
Tesidolumab
Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cuttin...
T76844 Abciximab 143653-53-6 98%
Abciximab
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leuk...
T76856 Andecaliximab 1518996-49-0 98%
Andecaliximab
Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model o...
T76857 Anetumab 1954758-84-9 98%
Anetumab
Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-act...
T76858 Ascrinvacumab 1463459-96-2 98%
Ascrinvacumab
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1. Ascrinvacumab has a Kd value of 7 nM for human ALK1. Ascrinvacumab has ...
T76861 Cinpanemab 2094516-02-4 98%
Cinpanemab
Cinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease an...
T76863 Elezanumab 1791416-49-3 98%
Elezanumab
Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 ...
T76864 Enapotamab 1912423-61-0 98%
Enapotamab
Enapotamab is an AXL/UFO-related antibody that can be used to synthesize antibody-drug couplings (Enapotamab Vedotin).
T76866 Icrucumab 1024603-92-6 98%
Icrucumab
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab ...
T76867 Ravulizumab 1803171-55-2 98%
Ravulizumab
Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity...
T76870 Narsoplimab 2108782-45-0 98%
Narsoplimab
Narsoplimab (OMS 721) is a selective whole-human immunoglobulin gamma-4 (IgG4) monoclonal antibody, a mannan-binding lectin-associated serine protease-2 (MASP-2)...
T76873 Nidanilimab 2171061-85-9 98%
Nidanilimab
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. Nidanilimab has antitumor activity, cutting off the IL1α and IL1β...
T76874 Erenumab 1582205-90-0 98%
Erenumab
Erenumab is a whole-human monoclonal antibody. Erenumab inhibits calcitonin gene-related peptide (CGRP) receptors. Erenumab can be used to prevent migraine attac...
T76877 Vofatamab 1312305-12-6 98%
Vofatamab
Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combinatio...
T76882 Talquetamab 2226212-40-2 98%
Talquetamab
Talquetamab (JNJ-64407564) is a T-cell retargeting GPRC5D bispecific antibody for multiple myeloma with antitumor activity that induces T-cell-mediated killing o...
T76883 Talacotuzumab 1826831-79-1 98%
Talacotuzumab
Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affin...
T76884 Spesolimab 2097104-58-8 98%
Spesolimab
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. IL-36 plays an important role in the immune system and is associated with a reduction in biom...
Ganitumab
T76810
Ganitumab (AMG 479) is a highly potent monoclonal antibody to type 1 insulin-like growth factor receptor (IGF1R). Ganitumab is recognized to bind to IGF1R at low...
Lexatumumab
T76815
Lexatumumab (GHS-ETR 2) is a human excitatory monoclonal antibody targeting TRAIL receptor 2 that has anticancer activity and induces apoptosis in malignant meso...
Sonepcizumab
T76828
Sonepcizumab (LT 1009) is a fully humanized monoclonal antibody against S1P. Sonepcizumab has anti-cancer activity and can be used to study metastatic renal cell...
Tesidolumab
T76831
Tesidolumab (LFG316) is a fully human IgG1/λ anti-C5 monoclonal antibody. Tesidolumab (LFG316) has an inhibitory effect on crovalimab and C5, blocking the cuttin...
Abciximab
T76844
Abciximab (C7E3) is a mouse/human chimeric monoclonal antibody that is a potent glycoprotein IIb/IIIa inhibitor. Abciximab has anti-platelet aggregation and leuk...
Andecaliximab
T76856
Andecaliximab is a recombinant IgG4 monoclonal antibody targeting matrix metalloproteinase 9 (MMP9). Andecaliximab showed antifibrotic effects in a mouse model o...
Anetumab
T76857
Anetumab is a novel fully human anti-mesothelin IgG1 antibody that is a naked antibody to Anetumab ravtansine.Anetumab can be used to synthesize the antibody-act...
Ascrinvacumab
T76858
Ascrinvacumab (PF-03446962) is a highly humanized IgG2 monoclonal antibody against ALK-1. Ascrinvacumab has a Kd value of 7 nM for human ALK1. Ascrinvacumab has ...
Cinpanemab
T76861
Cinpanemab (BIIB054) is a novel human monoclonal antibody with affinity for alpha-synuclein residues 1-10. Cinpanemab can be used to study Parkinson's disease an...
Elezanumab
T76863
Elezanumab(ABT-555) is a potent human anti-RGMa monoclonal antibody.Elezanumab exerts its inhibitory effect on RGMa-mediated BMP signaling through the SMAD1/5/8 ...
Enapotamab
T76864
Enapotamab is an AXL/UFO-related antibody that can be used to synthesize antibody-drug couplings (Enapotamab Vedotin).
Icrucumab
T76866
Icrucumab ( IMC-18F1) is a humanized IgG1 monoclonal antibody targeting vascular endothelial growth factor receptor-1.Icrucumab has antitumor activity.Icrucumab ...
Ravulizumab
T76867
Ravulizumab (ALXN1210) is a humanized monoclonal antibody targeting complement factor 5 that specifically binds to human complement protein C5 with high affinity...
Narsoplimab
T76870
Narsoplimab (OMS 721) is a selective whole-human immunoglobulin gamma-4 (IgG4) monoclonal antibody, a mannan-binding lectin-associated serine protease-2 (MASP-2)...
Nidanilimab
T76873
Nidanilimab (CAN04) is a fully humanized IL1RAP monoclonal antibody with a Kd value of 1.10 pM. Nidanilimab has antitumor activity, cutting off the IL1α and IL1β...
Erenumab
T76874
Erenumab is a whole-human monoclonal antibody. Erenumab inhibits calcitonin gene-related peptide (CGRP) receptors. Erenumab can be used to prevent migraine attac...
Vofatamab
T76877
Vofatamab (B-701) is a fully human monoclonal antibody targeting FGFR3. Vofatamab has potential anticancer and antitumor activity and is often used in combinatio...
Talquetamab
T76882
Talquetamab (JNJ-64407564) is a T-cell retargeting GPRC5D bispecific antibody for multiple myeloma with antitumor activity that induces T-cell-mediated killing o...
Talacotuzumab
T76883
Talacotuzumab (JNJ 56022473) is an IgG1 fully humanized CD123 neutralizing monoclonal antibody containing a modified Fc structure. Talacotuzumab has a high affin...
Spesolimab
T76884
Spesolimab (BI 655130) is an anti-interleukin-36 receptor antibody. IL-36 plays an important role in the immune system and is associated with a reduction in biom...
1 2 3 4 5 6 7 8 9 10 11 12
TargetMol